FormentiSCDemariaS. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst2013; 105: 256–265.
2.
PitrodaSPChmuraSJWeichselbaumRR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol2019; 20: e434–e442.
3.
BatesJEMorrisCGMilanoMT,et al.Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: an analysis of the National Cancer Database. Radiother Oncol2019; 138: 75–79.
4.
KollerKMMackleyHBLiuJ, et al.Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther2017; 18: 36–42.
5.
QinROlsonASinghB, et al.Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys2016; 96: 72–77.
6.
TheurichSRothschildSIHoffmannM, et al.Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res2016; 4: 744–754.
7.
FioricaFTebanoUGabbaniM, et al.Beyond abscopal effect: a meta-analysis of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer. Cancers2021; 13: 2352.
8.
GiulianiJBonettiA. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res2019; 39: 3971–3973.
9.
ShaverdianNLisbergAEBornazyanK, et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol2017; 18: 895–903.
10.
TheelenWSMEChenDVermaV, et al.Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med2021; 9: 467–475.
11.
WelshJWHeymachJVGuoC,et al.Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J Immunother Cancer2020; 8: e001001.
12.
AzimiNAWelchHG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med1998; 13: 664.
